EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

GSK plc (LSE/NYSE: GSK) today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...

Insmed's promising drug pipeline includes Brensocatib and Arikayce. See why INSM stock is a strong pick with multi-billion ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut ...

[and] nasal polyps. This company has never lost its ability to develop new medicines, including the one that likely saved President-Elect Trump’s life when he caught Covid near the end of his ...

The randomized, double-blind, placebo-controlled ... chronic rhinosinusitis with nasal polyps, prurigo nodularis, atopic dermatitis, eosinophilic esophagitis, irritable bowel syndrome and food ...

The European Commission based its nod on the company’s POSEIDON phase 3 study, which was a double-blind, placebo-controlled ... chronic rhinosinusitis with nasal polyps (CRSwNP), a condition ...